Shoemaker quote IMCIVREE packaging IMCIVREE 3D Render -- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction -- Indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity -- -- Approval based on -18.4% placebo-adjusted BMI reduction achieved by setmelanotide in global Phase 3 TRANSCEND trial [N=142] -- -- Company to host conference call today at 7:00 p.m
Lab testing is required at the cost of $300.00, which includes CBC, CMP, Thyroid, Lipid, and HA1C labs
N Engl J Med 2016
Lets explore this complex topic and consider the various perspectives surrounding it
En savoir plus propos de nous Apprenez comment accder aux mdicaments En savoir plus Foire aux questions En savoir plus Comparer les mdicaments par maladie Avertissement Nous faisons tout notre possible pour garantir l'exactitude, l'actualit et l'exhaustivit des informations fournies ici, mais nous ne pouvons pas les garantir
After youve been approved for this treatment, youll start your series of injections
